Why Allakos Stock is collapsing today

What happened

Actions of Allakos (NASDAQ: ALLK) are down 88% as of 10:17 a.m. ET Wednesday. The huge drop came after the company announced the results of its Phase 3 Enigma 2 clinical studies and Phase 2/3 Kryptos clinical studies evaluating lireelimab.

Allakos reported that both clinical studies met their primary histological endpoints. However, neither of the two studies obtained statistically significant improvement on the symptomatic co-primary endpoints reported by the patients.

Image source: Getty Images.

So what

The biotech stock has plummeted so much because the primary endpoint failures weren’t even close. This is all the more problematic given that lireelimab is the only candidate in the Allokos pipeline in clinical development.

Patients in the Enigma 2 study who received placebo reported a greater absolute change in total symptom score (TSS) at six symptoms than patients receiving lireelimab. It was a similar story with the Kryptos study with patients receiving low doses of the drug. Patients receiving the high dose of lireelimab reported greater improvement in symptoms than those taking placebo, but this was not sufficient to be statistically significant.

The leaders of Allakos did not try to pass off the results as positive. CEO Robert Alexander said: “We are deeply disappointed that the studies did not reach their symptomatic results.” Chief Medical Officer Craig Paterson called the results “surprising and disappointing”.

Now what

Paterson said Allokos “currently” plans to continue analyzing data from both studies with the goal of determining a way forward for lireelimab in the treatment of eosinophilic gastrointestinal disease. The company also plans to continue development of a subcutaneous version of the drug targeting atopic dermatitis, asthma and spontaneous chronic urticaria.

10 stocks we prefer over Allakos Inc.
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They just revealed what they think are the ten best stocks investors can buy right now … and Allakos Inc. was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* Returns of the portfolio advisor as of December 16, 2021

Keith Speights has no position in the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

Comments are closed.